Nama's AI scorecard currently rates Vaxcyte Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PCVX report earnings?

Vaxcyte's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$2.13.

What is the PCVX price target?

The median analyst price target from 10 analysts is $121.00, with a range of $75.00 – $163.00.

Is PCVX Shariah compliant?

Nama's AAOIFI-style screen reads Vaxcyte as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Vaxcyte (PCVX)

Healthcare · Biotechnology · NASDAQ

Vaxcyte (PCVX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $10.11B and a free-cash-flow yield of -8.2%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +60.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-47.2%

How far the last close sits under the highest price of the past five years.

Market cap	$10.11B
Trailing P/E	—
Price / book	3.4
Price / sales	—
FCF yield	-8.2%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

PCVX earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$2.13). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$1.99	-$2.18	+8.7%	$0
Q2 2026	Aug 5, 2026	-$1.97	-$2.10	+6.2%	$0
Q1 2026	May 6, 2026	-$2.30	-$1.77	-29.9%	$0
Q4 2025	Feb 24, 2026	-$1.80	-$1.50	-20.0%	$0

PCVX analyst price target

Median target $121.00 from 10 analysts, ranging $75.00 – $163.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live PCVX data on Nama Insights →

Recent Congressional trades

Vaxcyte trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 6, 2025

PCVX FAQ

Is PCVX a buy?: Nama's AI scorecard currently rates Vaxcyte Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PCVX report earnings?: Vaxcyte's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$2.13.
What is the PCVX price target?: The median analyst price target from 10 analysts is $121.00, with a range of $75.00 – $163.00.
Is PCVX Shariah compliant?: Nama's AAOIFI-style screen reads Vaxcyte as Can't Tell. A figure the screen needs is missing, so it can't tell.